tbuckley/cabot-search huggingface dataset:
A multinational phase II study of liposome irinotecan (PEP02) for patients with gemcitabine-refractory metastatic pancreatic cancer.
Authors: A. H. Ko, M. A. Tempero, Y. Shan, W. Su, Y. Lin, E. Dito, A. Ong, G. Yeh, L. Chen
Journal: Journal of Clinical Oncology (2011)

237 Background: PEP02 is a novel nanoparticle liposome formulation of irinotecan (CPT-11) that has improved pharmacokinetics and tumor biodistribution of both CPT-11 and its active metabolite-SN38 compared to the free form drug. PEP02 has showed encouraging safety and efficacy in various tumor types, including significant antitumor activity in a human pancreatic cancer L3.6pl orthotopic nude mouse xenograft model. In previous phase I studies, PEP02 either alone or in combination with 5-FU/LV demonstrated prolonged disease control in 5 of 7 (71%) patients (pts) with gemcitabine (GEM)-refractory advanced pancreatic cancer (PC). This phase II study aims to evaluate PEP02 monotherapy as 2 nd -line treatment in pts with metastatic, GEM-refractory PC. Methods: Pts were eligible if they had metastatic pancreatic adenocarcinoma, KPS ≥ 70, and progressed following one line of GEM-based therapy. Treatment consisted of PEP02 120 mg/m 2 administered as a 90-minute infusion every 3 weeks. A Simon's 2-stage design was used with 16 pts in the first stage and 39 pts in total; primary objective was 3-month survival rate (OS 3-month ). Results: Between March 2009 and August 2010, 37 pts were enrolled at 3 centers in the U.S. and Taiwan. Characteristics for the first 31 evaluable pts: 13 M/18 F; age 39-82 yrs; 19 Asian/12 Caucasian, KPS 100/90/80/70: 5/14/4/8. Mean number of treatment cycles is 5 (range, 1-22). Disease control rate (minor response + stable disease &gt;2 cycles) is 52%. 8 of 24 pts (33%) with elevated baseline CA19-9 have had &gt;50% biomarker decline. To date, 23/31 pts (74%) have survived &gt; 3 months, with 4 pts still alive after 1 year. Reasons for study discontinuation: 74% progressive disease, 9% drug-related toxicity, 17% other. Preliminary safety data is available for the first stage. Most common G3/4 adverse events included: fatigue (31%), neutropenia (25%), nausea/vomiting (19%), and diarrhea (13%). Conclusions: This study has already met its primary endpoint (predicted OS 3-month &gt;65%). PEP02 appears to have both activity and tolerable side effects for pts with metastatic, GEM-refractory PC, and represents a promising option for this pt population with few standard options. [Table: see text]
Comparative Gene Expression Profiling of Leukemia Cells in Peripheral Blood and Tissue Compartments Reveals a Prominent Role of the Microenvironment for CLL Cell Proliferation.
Authors: Yair Herishanu, Patricia Perez-Gelen, Delong Liu, Angelique Biancotto, Berengere Vire, Federica Gibellini, Ndegwa Njuguna, Philip McCoy, Stefania Pittaluga, Maryalice Stettler-Stevenson, Peter J Munson, Wyndham H Wilson, Adrian Wiestner
Journal: Blood (2009)
Authors’ reply to Lees
Authors: Karin B Nelson, Thomas P Sartwelle, Dwight J Rouse
Journal: BMJ (2017)

As Lees mentions,12 children whose births were monitored electronically had significantly fewer seizures in the newborn period.3 Most data on fetal monitoring and neonatal seizures come from the large Dublin study.4 The meaning of this association is far from clear, as there were …
The role of risk factors on survival for patients with pancreatic cancer
Authors: K. Bagni, C. Dehlendorff, B.V. Jensen, A.Z. Johansen, P. Pfeiffer, C.P. Hansen, S.E. Nielsen, M.K. Yilmaz, N.H. Holländer, J. Johansen
Journal: Annals of Oncology (2016)
Erfe-Encoding FAM132B in Congenital Dyserythropoietic Anemia Type II
Authors: Roberta Russo, Immacolata Andolfo, Luigia De Falco, Francesco Manna, Antonella Gambale, Mariasole Bruno, Gianluca De Rosa, Domenico Girelli, Lucia De Franceschi, Achille Iolascon
Journal: Blood (2015)
MLN2238, a Novel and Potent Proteasome Inhibitor, Induces Caspase-Dependent Cell Death, Cell-Cycle Arrest, and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Chemotherapy Sensitive or Resistant B-Cell Lymphoma Cell Lines
Authors: Juan Gu, Patil Ritesh, Cory Mavis, George Deeb, John Gibbs, Francisco J. Hernandez-Ilizaliturri, Myron S. Czuczman
Journal: Blood (2010)
Efficacy and safety of BCD-022, trastuzumab biosimilar candidate, compared to herceptin: Results of international multicenter randomized double blind study in patients with HER2+ mBC
Authors: M. Shustova, O. Burdaeva, S. Alexeev, K. Shelepen, A. Khorinko, G. Mukhametshina, L. Sheveleva, R. Ivanov
Journal: Annals of Oncology (2016)
OS3.2 Delta-aminolevulinic acid can decrease the radioresistance of glioma stem cells with mesenchymal phenotypes in vitro and in vivo
Authors: Y. Park, N. Nonoguchi, N. Ikeda, N. Yoshikawa, T. Sato, Y. Mishima, Y. Kajimoto, Y. Narumi, J. Takahashi, T. Kuroiwa
Journal: Neuro-Oncology (2016)
Erratum: PGC-1 promotes insulin resistance in liver through PPAR-α-dependent induction of TRB-3
Authors: Seung-Hoi Koo, Hiroaki Satoh, Stephan Herzig, Chih-Hao Lee, Susan Hedrick, Rohit Kulkarni, Ronald M Evans, Jerrold Olefsky, Marc Montminy
Journal: Nature Medicine (2004)
Predictive Factors of Treatment Response to Hypomethylating Agents in Patients with Myelodysplastic Syndrome
Authors: Ping Wu, Xin Du, Jianyu Weng, Chengxin Deng, Suxia Geng, Zesheng Lu, Peilong Lai, Xin Huang, Chengwei Luo
Journal: Blood (2015)
Time to First Acute Exacerbation Can Stratify the Patients According to Their Prognosis during Clinical Course of Chronic GVHD: Evaluation of New End-Point for Chronic GVHD.
Authors: Dong Hwan Kim, Sang Kyun Sohn, Kun Soo Lee, Jong Gwang Kim, Kyu Bo Lee, Kyoo-Hyung Lee, Je-Hwan Lee, Seong-Jun Choi, Jung-Hee Lee
Journal: Blood (2005)
Demethylation of H3K27 Is Essential for the Induction of Direct Cardiac Reprogramming by miR Combo
Authors: Sophie Dal-Pra, Conrad P. Hodgkinson, Maria Mirotsou, Imke Kirste, Victor J. Dzau
Journal: Circulation Research (2017)

Rationale: Direct reprogramming of cardiac fibroblasts to cardiomyocytes has recently emerged as a novel and promising approach to regenerate the injured myocardium. We have previously demonstrated the feasibility of this approach in vitro and in vivo using a combination of 4 microRNAs (miR-1, miR-133, miR-208, and miR-499) that we named miR combo. However, the mechanism of miR combo mediated direct cardiac reprogramming is currently unknown. Objective: Here, we investigated the possibility that miR combo initiated direct cardiac reprogramming through an epigenetic mechanism. Methods and Results: Using a quantitative polymerase chain reaction array, we found that histone methyltransferases and demethylases that regulate the trimethylation of H3K27 (H3K27me3), an epigenetic modification that marks transcriptional repression, were changed in miR combo–treated fibroblasts. Accordingly, global H3K27me3 levels were downregulated by miR combo treatment. In particular, the promoter region of cardiac transcription factors showed decreased H3K27me3 as revealed by chromatin immunoprecipitation coupled with quantitative polymerase chain reaction. Inhibition of H3K27 methyltransferases or of the PRC2 (Polycomb Repressive Complex 2) by pharmaceutical inhibition or siRNA reduced the levels of H3K27me3 and induced cardiogenic markers at the RNA and protein level, similarly to miR combo treatment. In contrast, knockdown of the H3K27 demethylases Kdm6A and Kdm6B restored the levels of H3K27me3 and blocked the induction of cardiac gene expression in miR combo–treated fibroblasts. Conclusions: In summary, we demonstrated that removal of the repressive mark H3K27me3 is essential for the induction of cardiac reprogramming by miR combo. Our data not only highlight the importance of regulating the epigenetic landscape during cell fate conversion but also provide a framework to improve this technique.
Beyond clinical trials: a real life multicenter Italian experience on Fulvestrant 500mg in postmenopausal women with hormone-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (MBC)
Authors: R. Palumbo, A. Ferzi, A. Gambaro, B. Tagliaferri, F. Sottotetti, L. Licata, C. Teragni, E. Pozzi, A. Bernardo
Journal: Annals of Oncology (2016)
qPCR MRD Monitoring in Peripheral Blood May Predict Hematological Relapse in Pediatric Acute Myeloid Leukemia
Authors: Kristian L Juul-Dam, Charlotte G Nyvold, Hans B Ommen, Olafur G Jonsson, Birgitte Lausen, Kirsi Jahnukainen, Henrik Hasle
Journal: Blood (2015)
Modulation of Tryptophan Catabolism by Acute Myeloid Leukemia Cells Acts as a General Mechanism of Immune Tolerance Via the Induction of T Regulatory Cells.
Authors: Antonio Curti, Valentina Salvestrini, Michela Aluigi, Sara Trabanelli, Emanuela Ottaviani, Ilaria Durelli, Alberto L. Horenstein, Francesca Fiore, Massimo Massaia, Milena Piccioli, Stefano Pileri, Giovanni Martinelli, Michele Baccarani, Roberto M. Lemoli
Journal: Blood (2007)
Outcome of Patients with Double-Expressor Lymphomas (DELs) Treated with R-CHOP or R-EPOCH
Authors: Anita Aggarwal, Hind Rafei, Fadi Alakeel, Antoine Nafez Finianos, Min-Ling Liu, Ehab El-Bahesh, Joao L. Ascensao, Dalia Mobarek
Journal: Blood (2016)
Detection and Follow Up of BCR/ABL Translocation by Cromogen In Situ Hibridization with ABL Centromeric and Telomeric (T/C) Probe Pair. Molecular, Accurate and Inexpensive Assay.
Authors: Carlos Sergio Barragan, Silvia B. Hansson, Silvina A. Cicchini, Monica Tamashiro, Pablo G. Dinardo
Journal: Blood (2007)
Randomized phase 2 trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced, epidermal growth factor receptor (EGFR) mutation-positive (mt+), nonsquamous (NS) non-small cell lung cancer (NSCLC): Translational research and interim overall survival (OS)
Authors: J. Yang, Y. Cheng, H. Murakami, P.-C. Yang, J. He, K. Nakagawa, J.H. Kang, J.-H. Kim, R. Hozak, T. Nguyen, X. Wang, S. Enatsu, T. Puri, M. Orlando
Journal: Annals of Oncology (2016)
UGT1A1 genotype as an indicator of neutropenia for FOLFOXIRI with bevacizumab in patients with mCRC (QUATTRO study)
Authors: Eiji Oki, Takayuki Yoshino, Kei Muro, Yasunori Emi, Akihito Tsuji, Kentaro Yamasaki, Takeharu Yamanaka, Hideki Sakisaka, Takeshi Kato, Akiyoshi Kanazawa
Journal: Annals of Oncology (2016)
Imatinib for Chronic Myeloid Leukemia Patients: A Single Institution Experience
Authors: Suzan Alp, Ayse Salihoglu, Ahmet Emre Eskazan, Emine Gulturk, M. Cem Ar, Seniz Ongoren Aydin, Zafer Baslar, Ayse Nur Buyru, Ugur Ozbek, A. Burhan Ferhanoglu, Yildiz Aydin, Teoman Soysal
Journal: Blood (2011)
Preclinical validation of a new tumor imaging agent targeting aVb3 to detect breast tumor using NIR-light imaging
Authors: F. Beurrier, I. Treilleux, Y. Chen, E. Froc, P. Gayet, S. Guillermet, P. Rizo, N. Chopin, C. Faure, D. Dammaco, S. Klinger, D. Ferraioli, G. Garin, A. Dutour
Journal: Annals of Oncology (2016)
Pitfalls of NICE recommendations on fertility treatment
Authors: Gulam Bahadur, Bryan Woodward, Roy Homburg, Ansam Al-Habib, Asif Muneer
Journal: BMJ (2017)

Heneghan and colleagues rightly highlight non-evidence based fertility practices,1 but we disagree with Spencer and colleagues’ recommendation in BMJ Open that the National Institute for Health and Care Excellence (NICE) and the Human Fertilisation and Embryology Authority (HFEA) should provide fertility guidance on what should be offered.2

The HFEA has no legal jurisdiction in providing clinical guidance while NICE has not provided evidence for firstline treatment options.3 The original NICE guideline stating that IVF should be offered over …
NCOG-07. PEDIATRIC TECTAL PLATE GLIOMAS AND THE EFFECTS OF TREATMENT ON ATTENTION
Authors: Jeffrey Murray, Beth Colaluca, Emily Brown, Richard Brown
Journal: Neuro-Oncology (2016)

Adequately treated hydrocephalus is linked to attention problems in children. Few studies have specifically evaluated patients with tectal plate glioma (TPG)-associated obstructive hydrocephalus. Gass et al. (2015) conducted a review of clinical outcomes in children treated for TPG and found that subjects exhibited difficulties with problem solving, planning, impulsivity, cognitive flexibility, processing speed and sustained attention. Aarsen et al (2013) investigated long-term outcomes in 12 children with tectal tumors and found significant deficits with sustained attention and long-term memory. The present study aims to further investigate aspects of attention that may be impacted by treated hydrocephalus associated with pediatric TPG. Neuropsychological assessment data for seven subjects aged 7-17 years (M=11.28; SD=3.30) were analyzed. The Connors Continuous Performance Test (CPT) was administered to subjects 1-8 years following shunt, endoscopic ventriculostomy or both. CPT measures of omission (inattentiveness), commission (impulsivity), Hit Reaction Time (reaction time) and Hit Reaction Time Inter-Stimulus Intervals Change (sustained attention) were obtained for each subject. Four subjects scored in the average range for omission errors, one scored below average and two exhibited scale elevations. A one-sample Kolmogorov-Smirnoff test indicated the standardized T-scores for inattentiveness were not normally distributed (M=55.71, SD=14.17, p < 0.005). Similar analyses for impulsivity, reaction time and sustained attention were not statistically significant. Three subjects demonstrated slightly fast reaction times, three performed in the average range and one showed slowed reaction time. Although two subjects scored in the average range on the sustained attention variable, three displayed scale elevations. All subjects demonstrated at least one score outside of the average range: 43% for inattentiveness and impulsivity; 57% for reaction time and 71% for sustained attention. These findings suggest that children treated for tectal plate glioma with hydrocephalus are at risk for long term deficits for several aspects of attention and that further study is warranted.
Predictive value of CD24 ala/val polymorphism for pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.
Authors: F. Marme, W. Werft, A. Benner, B. Burwinkel, H. Sinn, C. Sohn, P. Lichter, M. Hahn, P. Altevogt, A. Schneeweiss
Journal: Journal of Clinical Oncology (2010)

543 Background: Cytoplasmic expression of CD24, a GPI-anchored glycoprotein, is a strong prognostic factor for breast cancer and many other solid tumors. Recently, two polymorphisms in the CD24 gene (rs8734, rs3838646) have been linked to disease risk and progression in multiple sclerosis (MS), systemic lupus erythematodes (SLE) as well as the risk and progression of chronic hepatitis B infection. This study was designed to evaluate the clinical relevance of these polymorphisms in breast cancer with respect to their potential to predict a pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) for primary breast cancer (PBC), one of the strongest prognostic factors in this setting. Methods: 257 patients were randomized to either doxorubicin/cyclophosphamide (AC) or doxorubicin/pemetrexed (AP) both followed by docetaxel (Doc) as NCT for T2-4 N0-2 M0 PBC as part of an international, multicentric, randomized phase II trial. Both CD24 polymorphisms were analyzed on germline DNA and correlated with clinicopathologic variables and pCR. Results: There were no significant associations between either polymorphism and any of the clinicopathologic variables. In a multivariate analysis of both treatment arms, CD24 Val/Val genotype (rs8734) was the only significant predictor of pCR (OR: 4.97; p = 0.003). A test for interaction between CD24 Ala/Val genotype and treatment was negative (p = 0.49) and the predictive potential of this SNP was significant in both treatment arms. There was no correlation between CD24 3′UTR (TG/Del) genotype and pCR. Data on associations between genotype and CD24 expression as well as tumor associated lymphocytes will be presented. Conclusions: The CD24 Ala/Val SNP is a strong and independent predictor of pCR after NCT for EBC. Further evaluation of this predictive marker is clearly warrented. No significant financial relationships to disclose.
Allergic respiratory disease: Different allergens, different symptoms
Authors: A. Valero, S. Quirce, I. Dávila, J. Delgado, J. Domínguez‐Ortega
Journal: Allergy (2017)

Abstract Background Spanish population is rather homogeneous in its genetic and sociocultural characteristics, but allergen sensitization shows wide geographical variations. We aimed at assessing whether sensitization to different allergens in the diverse geographical areas induced different clinical and quality‐of‐life characteristics in adult patients with a first‐time diagnosis of rhinitis and/or asthma. Methods Two sequential, identically designed studies were carried out to evaluate such associations ( PERFILAR I and II ). PERFILAR II was an extension of PERFILAR I with additional allergens being included. Both phases were epidemiological, descriptive, cross‐sectional, nonintervention multicenter studies. Participants were required to have lived for at least the last 2 years in the geographical zone. Asthma control assessment was based on ACQ ‐5. Health‐related quality of life was evaluated with validated scales for rhinitis ( ESPRINT ‐15) and asthma (Mini‐ AQLQ ). Skin prick tests were used to identify sensitization to involved allergens. Results A total of 301 physicians recruited 2711 patients for PERFILAR I+ II . Sensitization to allergens was significantly different in patients with rhinitis with/without asthma. Seasonal allergens were associated with rhinitis, a longer time to asthma development, and more severe and commonly intermittent rhinitis. HDM were associated with more common rhinitis, and Alternaria was associated with asthma. The study confirms an association of geographical areas with relevant allergens and allergic clinical picture. Conclusion Different types of aeroallergens and specific sensitization profiles are associated with different allergic clinical pictures (rhinitis with/without asthma), different clinical symptoms, and different levels of severity. This could have implications to predict later clinical course and to select appropriate management approaches.
Hemophagocytic Lymphohistiocytosis (HLH) in Langerhans Cell Histiocytosis (LCH): A Multicenter Retrospective Descriptional Study
Authors: Deepak Chellapandian, Rui Zhang, Michael Jeng, Cor Van Den Bos, Vicente Santa-María López, Kai Lehmberg, Elena Sieni, Yini Wang, Taizo Allen Nakano, James Williams, Nicholas J. Fustino, Itziar Astigarraga, Ira Dunkel, Qi An, Cheng Cheng, Sheila Weitzman, Lillian Sung, Kim E. Nichols
Journal: Blood (2016)
The follow-up and lifestyle (FUCSAM project). Oncology Network of Piemonte and Valle d'Aosta: update 2017
Authors: M. Mistrangelo, F. Gallo, L. Giordano, D. Solerio, M.G. Bau, I. Romaniello, F. Pietribiasi, M.G. Pacquola, F. Castiglione, F. Sarli, C. Monagheddu, M. Ceccarelli, G. Ciccone, M. Mistrangelo, M. Viale, O. Bertetto
Journal: Annals of Oncology (2017)
CD56 Expression Is the Potent Prognostic Marker of the Thalidomide Efficacy in the Patients with Multiple Myeloma.
Authors: Akio Mori, Yutaka Tsutsumi, Satoshi Hashino, Hiroe Kanamori, Makoto Ibata, Shinobu Mashiko, Nobuo Masauzi, Masahiro Asaka, Masahiro Imamura
Journal: Blood (2005)
Early-onset gastric cancer: A distinct clinical entity with a different prognosis?
Authors: H. Santos Sousa, T. Bouca-Machado, E. Lima-da-costa, J. Pinto-de-Sousa, J. Preto, J. Sousa-Rodrigues, J. Costa-Maia
Journal: Journal of Clinical Oncology (2011)

22 Background: This study aimed to evaluate the early onset gastric cancer (EOGC), considered as gastric cancer in a patient younger than 45 years, as a distinct entity with a different prognosis. Methods: This study is related to 1,256 patients admitted with gastric or gastroesophageal junction carcinoma in our department between January 1988 and December 2008. There were 10.59% (133 cases) of EOGC in our series. The following clinical, pathological and staging parameters were studied: age, gender, tumor location, ressecability, type of resection surgery, type of resection, type of lymphadenectomy (Siewert and Japanese classifications), number of lymph nodes studied, tumor dimensions, macroscopic form, histological classification (Lauren and Ming), venous invasion, lymphatic permeation, perineural invasion, depth wall invasion (T), lymph node metastases (N) – TNM and Japanese classification and lymph node ratio – distance metastases (M) and stage. Results: Significant differences were observed in the type of resection surgery (p&lt;0.001) and type of lymphadenectomy (p=0.008), with more radical surgery performed in EOGC patients. Some tumor characteristics also showed significant differences: tumor dimensions (p=0.004), with EOGC usually smaller; diffuse type according to Lauren's classification (p&lt;0.001); infiltrative type according to Ming's classification (p=0.001); less venous invasion (p=0.005); less lymphatic permeation (p=0.029). There were no significant differences in the staging parameters. There were significant differences in the survival rate (p&lt;0.001), with 5-year survival rate of 44% in patients with EOGC compared with 31% in older patients. Cox-regression analysis revealed that age was an independent prognostic factor (HR 2,166, 1,133-4,139 CI 95%, p = 0.019), as well as depth wall invasion (T) and lymph node ratio. Conclusions: In this study, EOGC revealed to be a distinct clinical entity that presented differences in various clinico-pathological parameters. Despite EOGC presented more aggressive pathological characteristics, there was a better survival in this group, probably because the physical status of younger patients which allowed a more aggressive treatment. No significant financial relationships to disclose.